Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2026-03-30 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva reports 2025 full year results and provides a business update
Earnings Release Classification · 92% confidence The document is a press release titled “Inventiva reports 2025 full year results and provides a business update,” summarizing key financial metrics (revenues, cash runway, net loss, etc.), operational highlights, and conference call details. It is not the full annual report nor an investor presentation attachment but a standard quarterly/full-year earnings announcement. This fits the definition of an Earnings Release (Code: ER). FY 2025
2026-03-30 English
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité
Earnings Release Classification · 93% confidence The document is a press release announcing Inventiva’s full-year 2025 financial results, including revenue, cash position, net loss, per-share data, and a conference call date. It summarizes key annual performance metrics rather than providing the full statutory annual report (10-K). This matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-03-30 French
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Report Publication Announcement Classification · 88% confidence The document is a press release announcing the date and time for the release of the company’s 2025 full-year financial results and the accompanying conference call/webcast. It does not contain the actual financial results or detailed report itself, but rather schedules and links to the forthcoming publication and presentation. This matches the definition of a Report Publication Announcement (RPA).
2026-03-23 English
Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025
Report Publication Announcement Classification · 85% confidence The document is a press release announcing the future publication date of the company’s full annual financial results and the related conference call/webcast details. It does not contain the actual financial figures or detailed report content. It is essentially notifying investors of when and how the report will be released and presented. Under the “menu vs meal” rule, this is an announcement of a report publication and presentation rather than the report itself, matching the Report Publication Announcement category (RPA).
2026-03-23 French
Franchissements de seuils
Major Shareholding Notification Classification · 95% confidence The document is a formal French AMF filing under article L.233-7 of the French Commercial Code, detailing “déclarations de franchissements de seuils” by J.P. Morgan entities crossing 5% thresholds in Inventiva’s share capital and voting rights. This matches a Major Shareholding Notification (crossing thresholds).
2026-03-23 French
Franchissement de seuils
Major Shareholding Notification Classification · 95% confidence The document is a French regulatory disclosure under AMF rules (article L. 233-7 of the French Commercial Code) announcing that J.P. Morgan Chase & Co has crossed above the 5% ownership threshold in Inventiva. It details shareholding percentages, voting rights, and derivative contracts, which corresponds exactly to a Major Shareholding Notification. Therefore, the appropriate classification is MRQ.
2026-03-23 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.